8-K: Inotiv Reports 10.3% Revenue Increase in First Quarter of Fiscal 2024, Driven by Strong Growth in Research Models and Services

Inotiv, Inc. announced a 10.3% increase in revenue for the first quarter of fiscal year 2024, reaching $135.5 million, driven by growth in both its Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments.

Summary

• Inotiv's revenue for the first quarter of fiscal year 2024 reached $135.5 million, a 10.3% increase compared to $122.8 million in the same period last year.
• The Research Models and Services (RMS) segment saw an 11.1% revenue increase, reaching $90.8 million, while the Discovery and Safety Assessment (DSA) segment grew by 8.8% to $44.7 million.
• The company's net loss significantly improved to $15.8 million, or 11.7% of total revenue, compared to a net loss of $86.9 million, or 70.8% of total revenue, in the first quarter of fiscal year 2023.
• Adjusted EBITDA for the quarter was $9.6 million, or 7.1% of total revenue, a substantial improvement from a loss of $5.5 million, or -4.5% of total revenue, in the same quarter of the previous year.
• The DSA backlog increased to $152.3 million at the end of December 2023, up from $147.9 million at the end of December 2022 and $132.1 million at the end of September 2023.
• Inotiv completed the in-house integration of its North American transportation operations in the second quarter of fiscal 2024.
• The company completed expansion activities at its Fort Collins, CO facility by the end of October 2023, with the expanded site becoming operational in the second quarter of fiscal 2024.
• Inotiv closed the sale of its RMS facilities in Spain and France during the quarter.
• The company is continuing to execute its site optimization plan for its Blackthorn, UK site, with relocation of operations expected to be completed by the end of March 2024.
• The company reaffirmed its fiscal 2024 revenue guidance of $580 to $590 million and adjusted EBITDA guidance of $75 to $80 million.

Sentiment

Score: 8

Explanation: The document shows a strong positive trend with significant improvements in revenue, net loss, and adjusted EBITDA. The company is executing on its strategic initiatives and has reaffirmed its fiscal year guidance. The sentiment is positive, indicating a good investment opportunity.

Positives

• Revenue increased by 10.3% year-over-year, indicating strong growth.
• The net loss significantly decreased, showing improved profitability.
• Adjusted EBITDA turned positive, demonstrating improved operational efficiency.
• The DSA backlog increased, suggesting strong future revenue potential.
• The company successfully integrated its North American transportation operations in-house.
• Expansion activities at the Fort Collins facility were completed, increasing capacity.
• The company is executing its site optimization plan, which is expected to improve efficiencies.
• The company reaffirmed its fiscal 2024 revenue and adjusted EBITDA guidance.

Negatives

• The company still reported a net loss of $15.8 million for the quarter, although it is a significant improvement from the previous year.
• Cash and cash equivalents decreased from $35.5 million at the end of fiscal year 2023 to $22.0 million at the end of December 2023.
• Cash used in operating activities was $6.5 million for the quarter.

Risks

• The company's ability to manage recurring and unusual costs could impact future profitability.
• The company's ability to execute on its restructuring and site optimization plans and to realize the expected benefits related to such actions could impact future performance.
• The company's ability to service its outstanding indebtedness and to comply with financial covenants could impact future financial stability.
• Global economic conditions could impact the demand for the company's services and products.
• The company's ability to successfully integrate the operations and personnel related to acquisitions could impact future performance.

Future Outlook

Inotiv reaffirms its fiscal 2024 revenue guidance of $580 to $590 million and adjusted EBITDA guidance of $75 to $80 million. The company expects to remain in compliance with its financial covenants for the next 12 months and capital expenditures are expected to be approximately 4.5% of revenue in fiscal 2024.

Management Comments

• Robert Leasure Jr., President and Chief Executive Officer, stated that the company's transformation over the past 18 months has been significant, culminating in the optimization of the operational footprint from 35 to 24 locations.
• Mr. Leasure also noted the completion of the transition of transportation operations in-house, which will allow the company to better service customer demand and enhance margins.
• Mr. Leasure mentioned that the company has shifted to a renewed focus on sales and marketing as near-term infrastructure projects near completion.
• Mr. Leasure stated that the first quarter improvement in the DSA backlog was a positive and that the company plans to continue building on its strategic initiatives to improve efficiencies.

Industry Context

Inotiv's results reflect a positive trend in the contract research organization (CRO) industry, where demand for drug discovery and development services is increasing. The company's focus on operational efficiency and strategic initiatives aligns with industry trends towards cost optimization and improved service delivery. The growth in both DSA and RMS segments indicates a diversified approach to capturing market opportunities.

Comparison to Industry Standards

• Inotiv's 10.3% revenue growth is comparable to other mid-sized CROs, such as Charles River Laboratories (CRL) and WuXi AppTec, which have also reported solid growth in recent quarters, although specific growth rates vary.
• The improvement in Inotiv's adjusted EBITDA from a loss to a positive figure is a significant achievement, indicating progress in operational efficiency, which is a key focus for CROs globally.
• The DSA backlog increase to $152.3 million is a positive sign, suggesting strong future revenue potential, and is a key metric that investors use to assess the health of CROs.
• The company's site optimization plan, including the sale of facilities in Spain and France, is a common strategy among CROs to streamline operations and reduce costs, similar to actions taken by companies like Envigo (now part of Inotiv) and Labcorp.
• The in-house integration of transportation operations is a unique move that could provide a competitive advantage by improving service delivery and reducing costs, which is not a common practice among most CROs.

Stakeholder Impact

• Shareholders will likely view the improved financial results positively, potentially leading to an increase in share price.
• Employees may benefit from the company's improved financial stability and growth prospects.
• Customers may experience improved service delivery due to the company's operational improvements.
• Suppliers may benefit from the company's increased business activity.
• Creditors will likely view the company's improved financial performance and compliance with debt covenants positively.

Next Steps

• The company will continue to execute its site optimization plan, with the relocation of operations from Blackthorn, UK to Hillcrest, UK expected to be completed by the end of March 2024.
• The company will continue to focus on sales and marketing as near-term infrastructure projects near completion.
• Management will host a conference call on February 7, 2024, to discuss the first quarter results.

Key Dates

Keywords

Inotiv, contract research organization, CRO, nonclinical drug discovery, drug development, research models, safety assessment, revenue, EBITDA, backlog, site optimization, financial results